医学
人工耳蜗植入术
经迷路入路
期限(时间)
外科
人工耳蜗植入
听力学
放射科
磁共振成像
桥小脑角
量子力学
物理
作者
Anselm Joseph Gadenstaetter,Alice Barbara Auinger,Matthias Gerlitz,Dominik Riss,Erdem Yıldız,Karl Roessler,Christian Matula,Valerie Dahm,Christoph Arnoldner
标识
DOI:10.1097/mao.0000000000004313
摘要
Objective To evaluate the long-term hearing outcome after translabyrinthine resection of tumors within the internal auditory canal (IAC) with simultaneous cochlear implantation (CI). Study Design Prospective study. Setting Tertiary referral center. Patients Thirty-seven patients with tumors of the IAC undergoing translabyrinthine tumor surgery as a first-line therapy. Intervention(s) Intraoperatively, electrically evoked auditory brainstem response audiometry (eABR) was performed in all patients to assess cochlear nerve (CN) integrity. In case of preserved CN function after tumor removal, CI was subsequently performed. Postoperatively, patients were regularly followed up to evaluate pure-tone hearing as well as speech recognition with a monosyllabic word comprehension test. Main Outcome Measure(s) Postoperative hearing thresholds and word recognition scores. Results Of 37 included patients, 22 (59.46%) had positive eABR responses after tumor removal. Twenty-one of these underwent simultaneous CI directly after tumor surgery and were followed-up for 24.24 ± 19.83 months after surgery. Hearing of these patients significantly improved from 73.87 ± 21.40 dB preoperatively to a mean pure-tone average of 41.56 ± 18.87 dB 1 year ( p = 0.0008) and 34.58 ± 2.92 dB 3 years after surgery ( p = 0.0157). Speech recognition significantly recovered from 13.33 ± 25.41% to 58.93 ± 27.61% 1 year ( p = 0.0012) and 51.67 ± 28.58% 3 years postoperatively ( p = 0.0164). Conclusions Regardless of tumor histopathology, CI is an effective option to restore patients' hearing after translabyrinthine tumor surgery. After CI, patients hearing can be restored over a long-term period of a minimum of 3 years post-surgery. Furthermore, eABR proves to be a practical tool to evaluate CN function and screen for patients eligible for CI.
科研通智能强力驱动
Strongly Powered by AbleSci AI